Afatinib: all 164 studies that test it
Page 1 of 2. Open to participants first (16), then studies with results posted, then the rest; newest registration first within each.
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
- A Trial of the Combination of Afatinib and Palbociclib in Previously Treated Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06753747Phase 1/2
- Afatinib in Patients With Fanconi Anemia (FA) and Advanced Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT06648096Phase 1/2
- EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingNCT06486142Phase 3
- Pemigatinib + Afatinib in Advanced Refractory Solid TumorsRecruitingNCT06302621Phase 1
- Trastuzumab Deruxtecan(T-DXd) and Afatinib Combination in HER2-low Advanced Gastric CancerRecruitingNCT06085755Phase 1/2
- Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer PatientsRecruitingNCT06071013Phase 1/2
- Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR MutationsRecruitingNCT06062823Phase 2
- Palbociclib Combined With Afatinib for Advanced Squamous Carcinoma of Esophagus or Gastroesophageal JunctionRecruitingNCT05865132Phase 2
- To Evaluate the Efficacy and Safety of Afatinib for Advanced ALTRK-negative ESCCRecruitingNCT05818982Phase 2
- Study to Evaluate the Efficacy of Afatinib in Skull Base ChordomaNot yet recruitingNCT05519917Phase 2
- Pilot Trial for Treatment of Recurrent GlioblastomaRecruitingNCT05432518Early Phase 1
- Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerRecruitingNCT05267288Phase 2
- Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNARecruitingNCT04183712Phase 2
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2
- A Phase II Evaluation of Afatinib in Patients With Persistent or Recurrent HER2-positive Uterine Serous CarcinomaRecruitingNCT02491099Phase 2
- Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)Active, not recruitingNCT06385483Phase 2Results posted
- Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B)Active, not recruitingNCT04439136Phase 2Results posted
- Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungCompletedNCT03157089Phase 2Results posted
- Dual Inhibition of EGFR With Afatinib and Cetuximab in the Treatment of Advanced Squamous Cell Cancers of the Head and NeckCompletedNCT02979977Phase 2Results posted
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results posted
- Afatinib Monotherapy in Patients With ERBB-deregulated Metastatic Urothelial Tract Carcinoma After Failure of Platinum Based ChemotherapyCompletedNCT02780687Phase 2Results posted
- Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)TerminatedNCT02695290Phase 4Results posted
- Afatinib in NSCLC With HER2 MutationCompletedNCT02597946Phase 2Results posted
- Trial Using Gilotrif for Advanced Penile Squamous Cell CarcinomaTerminatedNCT02541903Phase 2Results posted
- Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderCompletedNCT02514174Phase 4Results posted
- Trial of Afatinib in Pediatric TumoursCompletedNCT02372006Phase 1/2Results posted
- Afatinib in NSCLC With HER2 MutationCompletedNCT02369484Phase 2Results posted
- The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant SettingTerminatedNCT02271906Phase 2Results posted
- Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) MutationCompletedNCT02208843Phase 4Results posted
- Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)CompletedNCT02191891Phase 1Results posted
- LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT02131155Phase 3Results posted
- Afatinib in Advanced Refractory Urothelial CancerTerminatedNCT02122172Phase 2Results posted
- Clinical Study for the Treatment of Breast Cancer: the Patient Will Receive Afatinib Plus Letrozole or Letrozole AloneTerminatedNCT02115048Phase 2Results posted
- Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) MutationsCompletedNCT02044380Phase 3Results posted
- Trial of Afatinib (BIBW 2992) + Cetuximab in Advanced Solid TumoursCompletedNCT02020577Phase 1Results posted
- Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)CompletedNCT01999985Phase 1Results posted
- Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR MutationCompletedNCT01953913Phase 3Results posted
- LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01856478Phase 3Results posted
- An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)CompletedNCT01853826Phase 3Results posted
- Afatinib After Chemoradiation and Surgery in Treating Patients With Stage III-IV Squamous Cell Carcinoma of the Head and Neck at High-Risk of RecurrenceTerminatedNCT01824823Phase 2Results posted
- ADAM-Afatinib Diarrhea Assessment and ManagementCompletedNCT01814553Phase 3Results posted
- A Phase I/II Study Afatinib/Carboplatin/Paclitaxel Induction Chemotherapy In HPV-Negative HNSCC.TerminatedNCT01732640Phase 1/2Results posted
- BIBW 2992 as add-on to Gem/Cis in Advanced Biliary Tract CancerTerminatedNCT01679405Phase 1Results posted
- LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based ChemotherapyCompletedNCT01523587Phase 3Results posted
- Afatinib and Paclitaxel in Patients With Advanced HER2-Positive Trastuzumab-Refractory Advanced Esophagogastric CancerCompletedNCT01522768Phase 2Results posted
- LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the LungCompletedNCT01466660Phase 2Results posted
- Lux-Breast 3; Afatinib Alone or in Combination With Vinorelbine in Patients With Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer Suffering From Brain MetastasesCompletedNCT01441596Phase 2Results posted
- Investigation of Ritonavir Effects on Afatinib Exposure in Healthy SubjectsCompletedNCT01426958Phase 1Results posted
- Drug Interaction Study With Rifampicin and AfatinibCompletedNCT01396265Phase 1Results posted
- LUX-Head&Neck 1: A Phase III Trial of Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic (R/M) Head and Neck Squamous Cell Cancer After Platinum Based ChemotherapyCompletedNCT01345682Phase 3Results posted
- LUX-Head&Neck 2: A Phase III Trial of Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapyTerminatedNCT01345669Phase 3Results posted
- Influence of Mild and Moderate Hepatic Impairment on the Pharmacokinetics, Safety and Tolerability of Various Doses of AfatinibCompletedNCT01298063Phase 1Results posted
- LUX-Breast 2; Afatinib in HER2 (Human Epidermal Growth Factor Receptor)-Treatment FailuresCompletedNCT01271725Phase 2Results posted
- BIBW 2992 (Afatinib) and Vinorelbine in Japanese Patients With Advanced Solid TumoursCompletedNCT01214616Phase 1Results posted
- An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid TumoursCompletedNCT01206816Phase 1Results posted
- BIBW 2992 (Afatinib) in Combination With Pemetrexed in Advanced Solid TumoursCompletedNCT01169675Phase 1Results posted
- A Study of BIBW 2992 (Afatinib) in Patients With Metastatic Colorectal CancerCompletedNCT01152437Phase 2Results posted
- LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin TreatmentCompletedNCT01125566Phase 3Results posted
- BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)CompletedNCT01121393Phase 3Results posted
- Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung CancerCompletedNCT01090011Phase 1Results posted
- LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or GefitinibCompletedNCT01085136Phase 3Results posted
- Understanding Mechanisms of Acquired Resistance to BIBW2992CompletedNCT01074177Not applicableResults posted
- A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]CompletedNCT01003899Phase 2Results posted
- Phase I Dose Escalation Study of Concomitant BIBF 1120 and BIBW 2992 in Patients With Advanced Solid Tumours.CompletedNCT00998296Phase 1Results posted
- Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune®) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or GefitinibCompletedNCT00993499Phase 1Results posted
- Phase I Open Label Trial to Assess Safety of BIBW 2992 (Afatinib) in Combination With Herceptin® in Patients With HER2-positive Advanced Breast Cancer.CompletedNCT00950742Phase 1Results posted
- BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR MutationCompletedNCT00949650Phase 3Results posted
- Afatinib (BIBW 2992) QTcF Trial in Patients With Relapsed or Refractory Solid TumoursCompletedNCT00875433Phase 2Results posted
- 6 Weeks Treatment of Locally Advanced Breast Cancer With BIBW 2992 (Afatinib) or Lapatinib or TrastuzumabCompletedNCT00826267Phase 2Results posted
- Trial Exploring Afatinib (BIBW 2992) + Paclitaxel (Part A), Afatinib + Paclitaxel + Bevacizumab (Part B), Afatinib + Carboplatin (Part C) and Afatinib+ Paclitaxel +Carboplatin(Part D) in Patients With Advanced Solid TumoursCompletedNCT00809133Phase 1Results posted
- BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) PatientsCompletedNCT00796549Phase 2Results posted
- Phase II Trial of BIBW 2992 (Afatinib) in Genetically Pre-screened Cancers With EGFR and/or HER2 Gene Amplification.TerminatedNCT00748709Phase 2Results posted
- Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC PatientsCompletedNCT00730925Phase 2Results posted
- BIBW 2992 (Afatinib) With or Without Daily Temozolomide in the Treatment of Patients With Recurrent Malignant GliomaCompletedNCT00727506Phase 2Results posted
- Study to Determine the Maximum Tolerated Dose of BIBW 2992 (Afatinib) When Combined With Cisplatin/Paclitaxel or Cisplatin/5-FU in Patients With Advanced Solid TumoursCompletedNCT00716417Phase 1Results posted
- LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or GefitinibCompletedNCT00711594Phase 2Results posted
- BIBW 2992 and Letrozole in Hormonoresistant Metastatic Breast CancerCompletedNCT00708214Phase 2Results posted
- A Multi-centre 3-arm Randomised Phase II Trial of BIBF 1120 Versus BIBW 2992 Versus Sequential Administration of BIBF 1120 and BIBW 2992 in Patients With Hormone-resistant Prostate CancerCompletedNCT00706628Phase 2Results posted
- BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)CompletedNCT00656136Phase 3Results posted
- LUX Lung 2 Phase II Single Arm BIBW 2992 "Afatinib" in NSCLC With EGFR Activating MutationsCompletedNCT00525148Phase 2Results posted
- BIBW 2992 (Afatinib) in Head & Neck CancerCompletedNCT00514943Phase 2Results posted
- Phase II Trial of BIBW 2992 in Patients With HER2-positive Metastatic Breast Cancer After Failure of Trastuzumab TherapyCompletedNCT00431067Phase 2Results posted
- An Open Label Phase II Trial of BIBW 2992 in Patients With HER2-negative Metastatic Breast CancerCompletedNCT00425854Phase 2Results posted
- A Clinical Trial of Neoadjuvant Targeted Therapy, Immunotherapy, and Lysogenic HSV-Based Virotherapy in Resectable Head and Neck Squamous Cell CarcinomaActive, not recruitingNCT07010120Phase 1/2
- Exploratory Study of Inhaled Afatinib Dimaleate PK ProfileTerminatedNCT06897735Phase 1
- A Clinical Study on Neoadjuvant Treatment of Resectable Head and Neck Squamous Carcinoma With Immune-targeted Therapy and Lysogenic HSV VirusWithdrawnNCT06741982Phase 1
- Low-dose Radiotherapy Plus Tislelizumab in Combination With Afatinib for Neoadjuvant Treatment of Surgically Resectable Head and Neck Squamous CarcinomaCompletedNCT06494189Phase 1
- Neoadjuvant Tislelizumab With Afatinib for Resectable Head and Neck Squamous Cell CarcinomaCompletedNCT05517330Phase 2
- Neoadjuvant Chemotherapy, Tislelizumab With Afatinib for HNSCCCompletedNCT05516589Phase 2
- Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC TumorsCompletedNCT05298176Phase 2
- JMT101 Combined With Afatinib in Patients With Advanced Esophageal Squamous Cell Carcinoma After Standard TherapyStatus unknownNCT05164848Phase 1
- Study of Afatinib in Advanced Cutaneous Squamous Cell CarcinomaActive, not recruitingNCT05070403Phase 2
- Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR AmplificationStatus unknownNCT04880811Phase 2
- BI-754091 and Afatinib for Refractory Esophageal Squamous Cell Carcinoma (BEAR Study)CompletedNCT04839471Phase 2
- To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 FusionStatus unknownNCT04814056Phase 4
- A Biomarker-implemented Clinical Study Evaluating Mutations in MET and TP53 in a Population of Treatment-refractory Squamous Cell CarcinomaStatus unknownNCT04533321Phase 2
- Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLCActive, not recruitingNCT04497584Phase 2
- Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating MutationStatus unknownNCT04470076Phase 2
- AFAMOSI: Efficacy and Safety of Afatinib Followed by Osimertinib Compared to Osimertinib in Patients with EGFRmutated/T790M Mutation Negative Nonsquamous NSCLCActive, not recruitingNCT04413201Phase 4